Related Experiment Video
Updated: Mar 30, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines
Wui-Jin Koh1, Benjamin E Greer1, Nadeem R Abu-Rustum1
1From Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Washington/Seattle Cancer Care Alliance; Memorial Sloan Kettering Cancer Center; Moffitt Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; University of Michigan Comprehensive Cancer Center; Fox Chase Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; The University of Texas MD Anderson Cancer Center; University of Colorado Cancer Center; Roswell Park Cancer Institute; Huntsman Cancer Institute at the University of Utah; City of Hope Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Alabama at Birmingham Comprehensive Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Mayo Clinic Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred & Pamela Buffet Cancer Center at The Nebraska Medical Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Duke Cancer Institute; UC San Diego Moores Cancer Center; and National Comprehensive Cancer Network.
The National Comprehensive Cancer Network (NCCN) updated uterine sarcoma treatment guidelines, revising tumor classification and systemic therapy recommendations based on new data and clinical experience.
Area of Science:
- Oncology
- Gynecologic Oncology
- Cancer Research
Background:
- The National Comprehensive Cancer Network (NCCN) Guidelines for Uterine Neoplasms offer interdisciplinary treatment recommendations for endometrial carcinoma and uterine sarcomas.
- Previous guidelines established a framework for managing these gynecologic malignancies.
Purpose of the Study:
- To summarize key updates and discussions from the NCCN Uterine Neoplasms Panel regarding uterine sarcoma treatment.
- To detail revisions in tumor classification and systemic therapy recommendations for uterine sarcomas.
Main Methods:
- Review of NCCN Uterine Neoplasms Panel discussions from 2016.
- Incorporation of updates from the World Health Organization (WHO) tumor classification system.
- Revision of systemic therapy recommendations based on new data and clinical experience.
Main Results:
- Mesenchymal tumor classification was updated to align with the latest WHO tumor classification.
- Systemic therapy recommendations were revised to incorporate current evidence and collective clinical insights.
- The rationale behind these significant guideline changes is elaborated.
Conclusions:
- The updated NCCN Guidelines for Uterine Neoplasms reflect advancements in understanding and treating uterine sarcomas.
- These revisions aim to provide clinicians with the most current, evidence-based recommendations for patient care.
- The changes emphasize the importance of accurate tumor classification and optimized systemic therapies.
More Related Videos
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
